Avecho BiotechnologyAVEFF -74.14% EV-to-FCF is 78.34 as of Jul. 06, 2026. The stock has 2 warning signs investors should review. Among 330 Biotechnology companies, Avecho Biotechnology ranks worse than 84.55% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Avecho Biotechnology's Enterprise Value is $52.72 Mil.
Avecho Biotechnology's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was $0.67 Mil. Therefore, Avecho Biotechnology's EV-to-FCF for today is 78.34.
The historical rank and industry rank for Avecho Biotechnology's EV-to-FCF or its related term are showing as below:
AVEFF'
s EV-to-FCF Range Over the Past 10 Years
Min: -23.84 Med: -2.25 Max: 76.35
Current: 76.35
During the past 13 years, the highest EV-to-FCF of Avecho Biotechnology was 76.35. The lowest was -23.84. And the median was -2.25.
AVEFF's EV-to-FCF is ranked worse than 84.55% of 330
companies
in the Biotechnology industry
Industry Median: 16.3
vs AVEFF: 76.35
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Avecho Biotechnology's PE Ratio (TTM) for today is calculated as:
Avecho Biotechnology's share price for today is $0.0045.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Avecho Biotechnology's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.001.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Avecho Biotechnology EV-to-FCF Related Terms
Avecho Biotechnology EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Avecho Biotechnology's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Avecho Biotechnology's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Avecho Biotechnology EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Avecho Biotechnology's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Avecho Biotechnology's EV-to-FCF falls into.
Avecho Biotechnology's current Enterprise Value is $52.72 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Avecho Biotechnology's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was $0.67 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Avecho Biotechnology (AVEFF) has a EV-to-FCF of 78.34 as of Jul. 06, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Avecho Biotechnology and its competitors. According to the industry distribution chart, Avecho Biotechnology ranks #279 out of 330 companies in the Biotechnology industry, placing it in the top 84.5%.
Is Avecho Biotechnology's EV-to-FCF too high?
Avecho Biotechnology's current EV-to-FCF is 78.34. The Biotechnology industry median EV-to-FCF is 16.30. Avecho Biotechnology's value of 78.34 is 380.6% above this industry median. Based on the distribution chart, Avecho Biotechnology ranks #279 out of 330 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Avecho Biotechnology's EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Avecho Biotechnology ranks #279 out of 330 companies for EV-to-FCF. This places Avecho Biotechnology in the lower half of its industry. The industry median EV-to-FCF is 16.30. Avecho Biotechnology's value of 78.34 is 380.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 16.30, based on 330 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Avecho Biotechnology's current EV-to-FCF of 78.34 is 380.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Avecho Biotechnology and its competitors. For the Biotechnology industry, the median EV-to-FCF is 16.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Avecho Biotechnology's current EV-to-FCF is 78.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avecho Biotechnology stock overvalued right now?
Avecho Biotechnology (AVEFF) has a current EV-to-FCF of 78.34. The current EV-to-FCF is 78.34 and 380.6% above the Biotechnology industry median of 16.30. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Avecho Biotechnology (AVEFF), the current EV-to-FCF is 78.34 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Avecho Biotechnology Ltd is a research-based biotechnology company engaged in the development, production, sales, and licensing of products incorporating its patented platform technology Tocopheryl Phosphate Mixture (TPM), for the pharmaceutical, skincare, and animal health and nutrition industries. Its segments include Production, Human Health, and other segments. The Production segment, which is the key revenue driver, manufactures and sells TPM and Vital ET for use in drug delivery and cosmetic formulations. The Human Health segment's portfolio covers the delivery of drugs through gels, injectables, and patches, including the conduct of research and development activities. It focuses on the development of patches, including TPM/Oxymorphone and TPM/Oxycodone.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AVEFF has been successfully added to your 